Prospective, Multicenter, 3-Year Trial of Laparoscopic Adjustable Gastric Banding with the MIDBAND™

Abstract

Prospective outcomes demonstrate the safety and efficacy of gastric banding over time using the MIDBAND. Individual growth modeling demonstrated that postoperative weight loss is strongly related to the frequency and consistency of follow-up visits.

3-Year Real-World Outcomes with the Swedish Adjustable Gastric Band™ in France

“…In the last decade, fewer than three dozen national bariatric surgery studies (16 large sample, retrospective, database analyses [46–61], 14 prospective surveys [1, 2, 62–73], and one ongoing [multi-article], nonrandomized, prospective controlled study [74]) have been published in the peer-reviewed literature, 14 of these featuring European countries. In the seven nationwide studies with ≥2-year follow-up data in morbidly obese patients (five observational AGB or AGB-inclusive studies and two French AGB surveys [2, 26, 58, 71, 74–76]), weight loss was less than or comparable to that of the current SAGB cohort.…”

“…The single prior French clinical trial of an AGB with 3-year follow-up, a study of the MIDBand (MID, Dardilly, France), was conducted in 13 centers (two academic, one public general hospital, 10 private clinics) in 262 morbidly obese adults, 193 of whom were included in the weight-loss analysis (26 % lost to follow-up). Mean baseline BMI was 41.8 with a reduction of 8.2–30.7 at 3 years; median EWL was 61.0 % [76]. Percentage EWL ranges reported at 2–3 years in the three prior French AGB studies, taken together with the French SAGB cohort study, are likely representative of current AGB weight loss outcomes in France.…”